Management

40+ years of experience in the pharmaceutical and biotechnology sectors, with the last 12 years as a CEO

Marc joined Abivax in May 2023. Prior to that, he led the successful sale of CinCor Pharma for up to USD 1.8B, subject to the achievement of certain milestones, to AstraZeneca in February 2023, after joining the firm in July 2021. Marc also led the sale of Corvidia Therapeutics in August 2020 to Novo Nordisk for USD 2.1B in total consideration after having joined the company as CEO in April 2018. He was the CEO of Ipsen from November 2010 to July 2016, overseeing the development of its US presence. Prior to that, Marc worked for Amgen and Eli Lilly in jobs of increasing responsibilities in various international markets. He has served as Chairman of the Board of Ipsen since 2016 and has been a member of the board of directors of Claris Bio since 2020. Marc has a degree in civil engineering from the Ecole des Travaux Publics in Paris, a master’s degree in international management (MIM) from Thunderbird School of Global Management, and an executive MBA from Harvard Business School.

Served as the CFO at Sanofi Pasteur MSD, a Lyon-based joint venture between Sanofi and Merck, and a leading force in human vaccines across Europe from 2012 to 2016

Didier joined Abivax in December 2016. During the previous 20-year period, he held a wide scope of senior finance positions at Sanofi, in Commercial Operations and then R&D, where he became Global R&D CFO. He started his career as an auditor at PricewaterhouseCoopers, after graduating from the Commercial Institute of Nancy (ICN), a leading French business school. He also holds a master’s degree in finance and accounting from University of Nancy, as well as a graduate diploma in finance and accounting (DESCF).

20 years of biopharmaceutical industry experience with deep expertise in IBD and medical affairs

Chris brings 20 years of biopharmaceutical industry experience spanning drug discovery and medical affairs, including broad cross-functional leadership across the development and commercialization lifecycle with deep expertise in IBD. He has led Global Medical Affairs at Abivax since 2023 and brings significant experience developing medical strategies, engaging with key opinion leaders, and advancing therapies through late-stage development and launch. Prior to joining Abivax in 2023, Chris held roles at CymaBay (formerly Metabolex), Baxter, Baxalta, Shire, Arena Pharmaceuticals, and Pfizer. He holds a PhD in Organic Chemistry from UCLA and a BS from California State Polytechnic University, Pomona.

25+ years of experience and a strong track record in talent acquisition and development

Ida has occupied different leading People Operations positions in the pharmaceutical and biotechnology industry. Prior to joining Abivax, Ida was Senior Vice President and Head of People, Talent, and Culture at CinCor Pharma, where she successfully managed and led the recruitment strategy and organizational design of the company during a period of strong growth. Ida holds a bachelor’s degree in pharmacy from the University of Toledo, Ohio, US.

Extensive technical and operational leadership experience across development and commercialization

Tim brings extensive biopharmaceutical technical and operational leadership experience and leads Abivax’s CMC, Quality, and IT functions. His experience spans manufacturing strategy, process and platform development, technical operations, and global commercial supply operations. Most recently, he served as Chief Technology Officer of Caribou Biosciences and previously was the CEO of Oxford Biomedica Solutions, and held senior leadership roles at Homology Medicines, Sarepta, Shire, UCB, and Biogen. Earlier in his career, Tim served as a fighter pilot in the US Air Force. He holds an MS/MBA from Troy State University and a BS from the United States Air Force Academy.

20 years of global biopharmaceutical leadership experience, including multiple leadership roles

Mr Nesrallah leads global commercial strategy and launch preparation as the company advances toward potential regulatory approval and market entry for obefazimod, bringing more than 20 years of global biopharmaceutical leadership experience with deep expertise in gastroenterology and immunology. Prior to joining Abivax, he held several senior leadership roles at Takeda, including Vice President and US Franchise Head for its inflammatory bowel disease business, where he drove significant growth for Entyvio while expanding treatment access for patients. He also served as General Manager for Belgium and Luxembourg and later established and led Takeda’s International Marketing & Commercial Excellence organization, building integrated commercial capabilities across more than 60 countries to support launch readiness and portfolio growth. Earlier in his career, Mr Nesrallah held commercial leadership roles at Novartis and began his career at McKinsey & Company. He holds an MBA from the Richard Ivey School of Business and a Bachelor of Science in Biochemistry from the University of Ottawa.

25+ years of experience in marketing, sales, and business development within the pharmaceutical industry (13 years based in Japan)

Pierre was appointed Chief Business Officer in May 2023. Prior to this appointment, he served as Chief Commercial Officer and Vice President, Business Development at Abivax. Before joining Abivax in April 2015, he was Senior Vice President, Sales and Marketing for Guerbet as well as Chief Executive Officer of Medex (a medical devices company owned by Guerbet) for 3 years. Starting in 2009, Pierre served as Vice President, Sales for Asia, Latin America, and EMEA and met the ambitious objective of optimizing commercial performance across these 3 regions. As President of Guerbet Japan and Vice President for Guerbet Asia, Pierre successfully managed the rollout of its Japanese subsidiary and led the development of other branches in Asia. He holds a pharmacy degree (Caen-France), a master’s degree in company management (IAE of Caen-France), a master’s degree in biological and medical sciences (Caen-France), and an MBA with honors from The University of Chicago Booth School of Business, US.

Extensive legal and compliance experience across the pharmaceutical and biotechnology industries, government, and private practice

Tom joined Abivax in November 2026, bringing extensive legal and compliance leadership experience across the global pharmaceutical and biotechnology industries. Most recently, he served as General Counsel of Akero Therapeutics, where he led the company’s legal, compliance, and corporate governance functions, providing strategic oversight of global Phase 3 clinical development, its acquisition by Novo Nordisk, and subsequent integration.

Previously, Tom held senior leadership positions at Mesoblast Limited and Lupin Pharmaceuticals, overseeing a broad range of global functions, including FDA compliance. He also played a key role in building global supply chains to support successful commercial launches and securing the first-ever FDA approval of an allogeneic cellular therapy.

Earlier in his career, Tom served as a federal prosecutor at the U.S. Department of Justice, representing the FDA in civil and criminal litigation and investigations. He also practiced at a leading international law firm, where he represented life sciences companies in FDA regulatory, compliance, and enforcement matters.

Tom earned his JD from Cornell Law School, an MPhil in Psychoanalytic Studies from Trinity College Dublin Ireland, and an AB in Political Science from the University of Chicago.

25+ years in clinical development, diagnostics, and biomarker research

Prior to joining Abivax in July 2024, David was Senior Vice President, Head of Biometrics and Data Management at Alumis Inc. As part of the founding management team at Alumis, he served as Chief Information Officer responsible for building up capabilities in Biometrics, IT, Facilities, and Investor Relations during the early days of the company. Before joining Alumis, David was Vice President of Biometrics, Data Science, and Digital Health at MyoKardia where he built the advanced analytics capabilities from the ground up to enable the successful completion of critical Phase 3 study design, data readouts, and New Drug Application submission of CAMZYOS^® (mavacamten) until the company's acquisition by Bristol Myers Squibb in 2020. Prior to MyoKardia, David spent 15 years at Roche/Genentech with increasing responsibilities leading and building biostatistics and strategic innovation functions. He began his pharmaceutical industry career at Eli Lilly and Abbott Laboratories after receiving his PhD in biostatistics with a minor in genetics from UCLA and completing post-doctoral research at Columbia University, New York, NY.

15 years of post-PhD experience in academia and the biopharmaceutical industry, with a track record in chronic diseases program management

Nadège joined Abivax in September 2023. Prior to that, Nadège led Program Management at small and large biotech and pharmaceutical companies. At Corvidia Therapeutics and CinCor Pharma, she helped build the key investigational programs for chronic inflammatory and cardiovascular diseases from the early days of the companies through their acquisition by Novo Nordisk and AstraZeneca, respectively. Nadège directed the R&D Program Management branch of the Astellas Institute for Regenerative Medicine, supporting cell therapy program expansion into multiple diseases. Before that, she led the cardiovascular programs at Moderna, where she helped develop and expand the alliance portfolio with AstraZeneca. Nadège received a PhD in Human Genetics from Pierre et Marie Curie (now Sorbonne) University in Paris, and completed her postdoctoral studies at Harvard Medical School.

15+ years of experience in immunomodulation and drug development

Maurus joined Abivax in September 2025. He is a seasoned immunologist with more than 15 years of experience in immunomodulation and drug development across multiple programs, modalities, and development stages. He brings extensive expertise in immunology—spanning discovery, translational research, and clinical development, including advanced therapies such as cell and gene therapy. Prior to joining Abivax, Maurus served as Vice President of Research at Sangamo Therapeutics, where he led and successfully advanced CAR-Treg programs for autoimmune diseases including multiple sclerosis and inflammatory bowel disease, with a focus on Crohn’s disease. Earlier in his career, he held research leadership roles at Baxter, Baxalta, Shire, and Takeda, contributing to translational programs and regulatory filings including INDs and BLAs. He holds a PhD in immunology from Humboldt University in Berlin and earned a degree in chemistry with a specialization in molecular biology from the University of Cologne, Germany.